CN110256346A - Phenanthridines ketone compounds and preparation method and application with BRD4 albumen inhibiting effect - Google Patents
Phenanthridines ketone compounds and preparation method and application with BRD4 albumen inhibiting effect Download PDFInfo
- Publication number
- CN110256346A CN110256346A CN201910601362.9A CN201910601362A CN110256346A CN 110256346 A CN110256346 A CN 110256346A CN 201910601362 A CN201910601362 A CN 201910601362A CN 110256346 A CN110256346 A CN 110256346A
- Authority
- CN
- China
- Prior art keywords
- compound
- cancer
- formula
- brd4
- ketone compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091005625 BRD4 Proteins 0.000 title claims abstract description 53
- 102100029895 Bromodomain-containing protein 4 Human genes 0.000 title claims abstract description 53
- -1 Phenanthridines ketone compounds Chemical class 0.000 title claims abstract description 45
- 238000002360 preparation method Methods 0.000 title claims abstract description 32
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 15
- 150000001875 compounds Chemical class 0.000 claims abstract description 34
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 10
- 229940121649 protein inhibitor Drugs 0.000 claims abstract description 10
- 239000012268 protein inhibitor Substances 0.000 claims abstract description 10
- 201000010099 disease Diseases 0.000 claims abstract description 8
- 150000003839 salts Chemical class 0.000 claims abstract description 8
- 239000002994 raw material Substances 0.000 claims abstract description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 28
- 150000003456 sulfonamides Chemical class 0.000 claims description 18
- 229940124530 sulfonamide Drugs 0.000 claims description 16
- 238000006243 chemical reaction Methods 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 9
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims description 8
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 claims description 7
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 7
- 229940125797 compound 12 Drugs 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 7
- 238000006396 nitration reaction Methods 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 238000006722 reduction reaction Methods 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 125000001424 substituent group Chemical group 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 150000002828 nitro derivatives Chemical class 0.000 claims description 4
- 201000009030 Carcinoma Diseases 0.000 claims description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 3
- 230000008859 change Effects 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 229910017604 nitric acid Inorganic materials 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 208000017897 Carcinoma of esophagus Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 206010033701 Papillary thyroid cancer Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010068771 Soft tissue neoplasm Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 150000001447 alkali salts Chemical class 0.000 claims description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 150000007529 inorganic bases Chemical class 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 210000002751 lymph Anatomy 0.000 claims description 2
- 230000001926 lymphatic effect Effects 0.000 claims description 2
- 230000003211 malignant effect Effects 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 claims description 2
- 125000001544 thienyl group Chemical group 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 claims 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 claims 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 claims 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 239000003054 catalyst Substances 0.000 claims 1
- 229940125904 compound 1 Drugs 0.000 claims 1
- 229940125773 compound 10 Drugs 0.000 claims 1
- 229940126543 compound 14 Drugs 0.000 claims 1
- 229940125758 compound 15 Drugs 0.000 claims 1
- 229940125782 compound 2 Drugs 0.000 claims 1
- 229940126214 compound 3 Drugs 0.000 claims 1
- 229940125898 compound 5 Drugs 0.000 claims 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- RZFVLEJOHSLEFR-UHFFFAOYSA-N phenanthridone Chemical compound C1=CC=C2C(O)=NC3=CC=CC=C3C2=C1 RZFVLEJOHSLEFR-UHFFFAOYSA-N 0.000 abstract description 32
- 238000011031 large-scale manufacturing process Methods 0.000 abstract description 2
- 239000002585 base Substances 0.000 description 41
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 31
- 238000005160 1H NMR spectroscopy Methods 0.000 description 17
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- 230000015572 biosynthetic process Effects 0.000 description 15
- 238000003786 synthesis reaction Methods 0.000 description 15
- 102000001805 Bromodomains Human genes 0.000 description 10
- 108050009021 Bromodomains Proteins 0.000 description 10
- 238000011160 research Methods 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- KTFDYVNEGTXQCV-UHFFFAOYSA-N 2-Thiophenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CS1 KTFDYVNEGTXQCV-UHFFFAOYSA-N 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 4
- 230000001973 epigenetic effect Effects 0.000 description 4
- SWBLLSQMOMPTMC-UHFFFAOYSA-N naphthalene-2-sulfonamide Chemical compound C1=CC=CC2=CC(S(=O)(=O)N)=CC=C21 SWBLLSQMOMPTMC-UHFFFAOYSA-N 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- VNGBWZWREQUEMN-UHFFFAOYSA-N 2-nitrophenanthridine Chemical class C1=CC=C2C3=CC([N+](=O)[O-])=CC=C3N=CC2=C1 VNGBWZWREQUEMN-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- KDYMNZFBASPUFA-UHFFFAOYSA-N phenanthridin-2-amine Chemical class C1=CC=C2C3=CC(N)=CC=C3N=CC2=C1 KDYMNZFBASPUFA-UHFFFAOYSA-N 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- HBEDSQVIWPRPAY-UHFFFAOYSA-N 2,3-dihydrobenzofuran Chemical class C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 description 2
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 2
- 241000208340 Araliaceae Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 108010042653 IgA receptor Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102100034014 Prolyl 3-hydroxylase 3 Human genes 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000002626 targeted therapy Methods 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- ZPQOPVIELGIULI-UHFFFAOYSA-N 1,3-dichlorobenzene Chemical compound ClC1=CC=CC(Cl)=C1 ZPQOPVIELGIULI-UHFFFAOYSA-N 0.000 description 1
- ICBPURKUPVLVCM-UHFFFAOYSA-N 1,5-dimethyl-2-phenylpyrazol-3-one;2-hydroxy-2-phenylacetic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1.CN1C(C)=CC(=O)N1C1=CC=CC=C1 ICBPURKUPVLVCM-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical class [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 102100033642 Bromodomain-containing protein 3 Human genes 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 208000034951 Genetic Translocation Diseases 0.000 description 1
- 238000003649 HTRF KinEASE Methods 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101000871851 Homo sapiens Bromodomain-containing protein 3 Proteins 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 238000003016 alphascreen Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229910052789 astatine Inorganic materials 0.000 description 1
- RYXHOMYVWAEKHL-UHFFFAOYSA-N astatine atom Chemical compound [At] RYXHOMYVWAEKHL-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
- 125000001450 benzylpenicillanyl group Chemical group CC1(S[C@H]2N([C@H]1C(=O)*)C([C@H]2NC(CC2=CC=CC=C2)=O)=O)C 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000006718 epigenetic regulation Effects 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 235000002867 manganese chloride Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical class C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000005053 phenanthridines Chemical class 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- 239000003279 phenylacetic acid Substances 0.000 description 1
- 229960004838 phosphoric acid Drugs 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000005059 solid analysis Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940032330 sulfuric acid Drugs 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/10—Aza-phenanthrenes
- C07D221/12—Phenanthridines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of phenanthridines ketone compounds and preparation method and application with BRD4 albumen inhibiting effect, which includes: the compound and its pharmaceutically acceptable salt of structure shown in formula (I)；The compound for containing the brand new of phenanthridone parent nucleus can inhibit in various degree BRD4 albumen, it can be used for preparing BRD4 protein inhibitor, it can also be used to prevent and treat disease relevant to BRD4 protein active, related disease type is extremely more, therefore its application range is extremely wide.The invention also discloses the preparation method of the phenanthridines ketone compounds, raw material sources are wide, easy to operate, mild condition, at low cost, are fully compatible for industrialization large-scale production.
Description
Technical field
The present invention relates to field of medicinal chemistry, and in particular to phenanthridines ketones derivant, they preparation method, contain these
The Pharmaceutical composition of compound and their medicinal usage, especially as the purposes of BRD4 protein inhibitor.
Background technique
In recent years, tumour becomes one of the main reason for leading to human death in global range.Tumour generally has totality
The features such as cure rate is low and high recurrence rate, therefore prevent, treat and inhibit tumor recurrence that there is important scientific research value, it realizes
The prevention and healing of tumour have comparable urgent and challenge.
The exception of epigenetic regulation is to lead to one of tumorigenic key factor.Current research discovery, BRD4 albumen
The epigenetic of mediation is abnormal closely related with the overexpression of oncogene and in close relations with the growing multiplication of cancer cell.BRD4
It is a member of Bromodomain and extra C-terminal domain (BET) protein family, due in anti-tumor aspect
Potential value, cause the very big concern of major drugmaker and scientific research institution.
BET albumen is also referred to as epigenetic identification albumen, can identify that the epigenetics information in cellular histone becomes
Change, and transmit activated cell division etc. signal.By taking leukaemia as an example, the gene mutation of BET albumen can interfere this in haemocyte
Kind signal transmission, causes sick cell uncontrollably to divide, thus insulting histoorgan.BRD3/BRD4's
The code area Bromodomain and NUT (nucleoprotein in testis) gene chromosomal translocation form BRD-NUT pattern of fusion proto-oncogene
It is the pathogenesis place of center line cancer, and BRD4 albumen participates in the positive evidence of tumor invasion process at present.
Research is, it was also found that include AML (leukaemia), Burkitt lymthoma, multiple bone in haematopoietic cancer simultaneously
In the model of myeloma and B cell acute lymphatic leukemia, directly will by combination of the interference BRD4 on the site MYC
MYC silencing.Since the isomers of known various MYC is the important regulatory factor of cell Proliferation and survival, and MYC is in many
A possible oncogene of overexpression in cancer, therefore Bromodomain Antagonism is also swollen to drive for MYC for the first time
Tumor generation provides an effect chance.
These results of study illustrate that BRD4 and kinds of tumors exist and maintain close ties with, especially be difficult to cure so far some or
It there is no and play a significant role in the tumour of effective treatment means, the research with relation between tumor provides new plan for oncotherapy
Slightly.By acting on the small molecule compound of BRD4 protein B romodomain structural domain, interference Bromodomain structural domain with
The specific binding of acetylated lysine influences transcriptional regulatory and other cell processes in tumour cell, may be implemented to swollen
The targeted therapy of tumor.
Therefore, BRD4 albumen is a very promising epigenetic novel targets, and acts on BRD4 albumen
The micromolecular inhibitor of Bromodomain structural domain also has broad application prospects in tumor research, and be possible to from
In develop new type antineoplastic medicine.
The selective depressant JQ1 and IBET151 of reported BRD4 albumen, crystal complex show this micromolecular
Inhibitor is just being incorporated in the acetylated lysine identification pocket of Bromodomain structural domain, to block
The acetylation regulation that Bromodomain structural domain mediates, therapeutic effect of these inhibitor in several cancers have been obtained
It confirms.
Currently, the micromolecular inhibitor structure type of BRD4 albumen is few and selectivity is prominent not enough, people couple are limited
The biological function of the domain protein containing Bromodomain and its carry out in-depth study in terms of antitumor potentiality.In addition, existing
BRD4 protein inhibitor function and effect wait to improve, mechanism needs to be furtherd elucidate, and therefore, find efficient, highly selective new
Type small molecule BRD4 protein inhibitor is a hot spot of the antitumor research of epigenetic.
Summary of the invention
The object of the present invention is to provide a kind of phenanthridines ketone compounds with BRD4 albumen inhibiting effect and preparations
Methods and applications, a kind of phenanthridines ketone compounds containing phenanthridone parent nucleus, the phenanthridines ketone compounds have good BRD4
Protein inhibiting activity and good anti-tumor activity can be applied in preparation BRD4 protein inhibitor, can also further apply
In preparing in anticancer drug, have a very broad application prospects.
A kind of phenanthridines ketone compounds with BRD4 albumen inhibiting effect, be formula (I) shown in structure compound and its
Pharmaceutically acceptable salt；
In formula (I), R is selected from C1~C6Alkyl, C3~C6Naphthenic base, 2,3- dihydro benzo furyl, is not taken thienyl
Generation or the phenyl and naphthalene being substituted with a substituent；The substituent group is halogen, cyano, hydroxyl, amino, sulfydryl, C1~C6Alkyl,
C1~C6Alkoxy, C1~C6Alkylamino or C1~C6Halogenated alkoxy.
“C1~C6Alkyl " refers to the linear chain or branched chain saturated hydrocarbyl with 1-6 carbon atom；"C3~C6Naphthenic base ", which refers to, to be had
The cyclic saturated hydrocarbon base of 3-6 carbon atom；" halogen " or " halogen " refers to halogen atom, including fluorine, chlorine, bromine, iodine and astatine；C1~C6Alcoxyl
Alkoxy is-O- alkyl (i.e.-O-C in base1~C6Alkyl, C1~C6Alkyl is defined as above)；C1~C6In alkylamino " alkylamino "
For-NH- alkyl (i.e.-NH-C1~C6Alkyl, C1~C6Alkyl is defined as above)；" halogenated alkoxy " refers to that hydrogen atom is taken by halogen atom
The alkoxy in generation.
The present invention has been designed and synthesized a series of containing phenanthridone parent nucleus by the crystal structure model of research BRD4 albumen
Brand new compound, and there is the compound shown by pharmacological tests good BRD4 albumen to inhibit to live
Property and good anti-tumor activity, have a very broad application prospects.
Preferably, R base is n-propyl, normal-butyl, phenyl, cyclopenta, cyclohexyl, 2- thienyl, 2- methoxyphenyl, 4-
The chloro- 2- methoxy of chlorphenyl, 2- chlorphenyl, 4- methoxyphenyl, 4- tert-butyl-phenyl, 3- cyano-phenyl, 2,4 dichloro benzene base, 5-
Base phenyl, 2- naphthalene or 2,3- Dihydrobenzofuranes -5- base.
The concrete structure formula of R base see the table below shown in 1:
Table 1
The particular compound title of above-mentioned preferred compound number 1~15 are as follows:
N- (6- oxo -5,6- dihydrophenanthridine -2- base) benzsulfamide (1)；
N- (6- oxo -5,6- dihydrophenanthridine -2- base) hexamethylene sulfonamide (2)；
Penta sulfonamide (3) of N- (6- oxo -5,6- dihydrophenanthridine -2- base) ring；
N- (6- oxo -5,6- dihydrophenanthridine -2- base) third sulfonamide (4)；
N- (6- oxo -5,6- dihydrophenanthridine -2- base) fourth sulfonamide (5)；
The chloro- N- of 4- (6- oxo -5,6- dihydrophenanthridine -2- base) benzsulfamide (6)；
4- methoxyl group-N- (6- oxo -5,6- dihydrophenanthridine -2- base) benzsulfamide (7)；
4- tert-butyl-n-(6- oxo -5,6- dihydrophenanthridine -2- base) benzsulfamide (8)；
3- cyano-N- (6- oxo -5,6- dihydrophenanthridine -2- base) benzsulfamide (9)；
The chloro- N- of 2- (6- oxo -5,6- dihydrophenanthridine -2- base) benzsulfamide (10)；
2- methoxyl group-N- (6- oxo -5,6- dihydrophenanthridine -2- base) benzsulfamide (11)；
The chloro- N- of 2- methoxyl group -5- (6- oxo -5,6- dihydrophenanthridine -2- base) benzsulfamide (12)；
N- (6- oxo -5,6- dihydrophenanthridine -2- base) thiophene -2- sulfonamide (13)；
N- (6- oxo -5,6- dihydrophenanthridine -2- base) naphthalene -2- sulfonamide (14)；
N- (6- oxo -5,6- dihydrophenanthridine -2- base) -2,3- Dihydrobenzofuranes -5- sulfonamide (15).
The BRD4 albumen rejection ability of above-mentioned preferred compound is stronger, is particularly suited for preparation BRD4 protein inhibitor.
The compound pharmaceutically acceptable salt include: formula (I) compound and acid formed acid salt and with it is inorganic
The basic salt that alkali is formed.
The acid is hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, benzene sulfonic acid, p-methyl benzenesulfonic acid, naphthalene sulfonic acids, lemon
Acid, tartaric acid, lactic acid, pyruvic acid, acetic acid, maleic acid, succinic acid, fumaric acid, salicylic acid, phenylacetic acid or tussol；It is described
Inorganic base be contain alkali metal cations, alkaline earth metal cation or ammonium cation salt.
The present invention also provides a kind of preparation methods of the phenanthridines ketone compounds of above-mentioned formula (I) structure, including walk as follows
It is rapid:
Wherein, R is consistent with definition described in formula (I)；
Step a is mixed acid nitrification, and step b is nitro reduction, and step c is sulfonamide reaction.
A kind of preparation method of the phenanthridines ketone compounds with BRD4 albumen inhibiting effect, comprising the following steps:
1) using formula A structure compound represented as raw material, in HNO3/H2SO4Nitration mixture under the conditions of carry out nitration reaction, obtain
To nitro compound shown in formula B structure；
2) nitro compound shown in formula B structure, obtains intermediate shown in formula C-structure after nitro-reduction reaction；
3) intermediate shown in formula C-structure obtains after sulfonamide reaction with sulfonyl chloride compound shown in formula D structure
To the phenanthridines ketone compounds of structure shown in formula (I).
Wherein, the R in formula D and the R in formula (I) have identical meanings.
Method particularly includes: using formula (A) compound represented as raw material, in HNO3/H2SO4Nitration mixture under the conditions of nitrified,
Intermediate (C) is obtained after nitro reduction, intermediate (C) progress sulfonamide reaction is finally obtained into target product.
In step 1), the condition of the nitration reaction are as follows: in -5~5 DEG C of 1~5h of progress, further preferably, -2~3
DEG C carry out 1.5~2.5h, most preferably, in 0 DEG C of progress 2h.
In step 2), the condition of the nitro-reduction reaction are as follows: iron powder and NH is added4Cl and second alcohol and water, 70
DEG C~90 DEG C react 1~3 hour, further preferably, 75 DEG C~85 DEG C react 1.5~2.5 hours, most preferably, at 80 DEG C
Reaction 2 hours.
In step 3), the condition of the sulfonamide reaction are as follows: in dichloromethane solvent, using pyridine as catalysis
Agent, 15 DEG C~35 DEG C are reacted 1~5 hour, and further preferably, 20 DEG C~30 DEG C are reacted 1~3 hour, most preferably, 25 DEG C of reactions
2 hours.
The preparation of the compounds of this invention selects the corresponding raw material to be according to the difference of substituent group and the differences of substituting group position
It can.
The invention also discloses a kind of pharmaceutical compositions, contain above compound and pharmaceutically acceptable auxiliary material, tool
Body includes: formula (I) compound or pharmaceutically acceptable salt and pharmaceutically acceptable carrier or figuration of therapeutically effective amount
Agent.
The present invention evaluates the BRD4 protein binding capacity of compound, it is found that compound provided by the invention can be not
Inhibit BRD4 albumen with degree, can be used for preparing BRD4 protein inhibitor.
Compound provided by the invention, which can be used for preparing prevention or/and treatment, the drug of related disorders, describedization with BRD4
Closing object can also be used in the drug of preparation treatment Bromodomain dependence disease.By acting on BRD4 protein B romodomain
The small molecule compound of structural domain interferes the specific binding of Bromodomain structural domain and acetylated lysine, influences tumour
Intracellular transcriptional regulatory and other cell processes, may be implemented the targeted therapy to tumour.
The disease includes: melanoma, Papillary thyroid carcinoma, cholangiocarcinoma, colon cancer, oophoroma, center line cancer, non-
Small Cell Lung Cancer, malignant lymphatic tumor, liver cancer, kidney, lung cancer, cancer of pancreas, bladder cancer, prostate cancer, breast cancer, cancer of pancreas,
Thyroid cancer, cutaneum carcinoma, colorectal cancer, cancer of pancreas, oophoroma, breast cancer, carcinoma of testis, osteocarcinoma, the cancer of the brain, the cancer of the esophagus, stomach and intestine
Road cancer, soft-tissue tumor, leukemia, lymph cancer.
BRD4 albumen external activity test shows that compound provided by the present invention has significant BRD4 protein binding energy
Power, since BRD4 has key effect in growth of tumour cell proliferation and has external protein inhibiting activity experiment to support, this
Compound provided by inventing can be used for preventing or treating in the drug of disease related with BRD4 inhibitor, especially tumour
Drug in.
Compared with the existing technology, the beneficial effects of the present invention are embodied in:
The present invention provides a kind of compound containing phenanthridone parent nucleus, which can inhibit in various degree BRD4 egg
It is white, it can be used for preparing BRD4 protein inhibitor, it is good anti-for preventing and treating disease related with BRD4 protein inhibitor
Tumor promotion, the kinds of Diseases are extremely more, therefore its application range is extremely wide.In addition, the raw material sources of preparation method of the present invention
Extensively, easy to operate, mild condition, at low cost, it is fully compatible for industrialization large-scale production.
Detailed description of the invention
Fig. 1 is the nuclear magnetic spectrum of compound 12 in the present invention；
Fig. 2 is the carbon spectrum of compound 12 in the present invention；
Fig. 3 is the high resolution mass spectrum of compound 12 in the present invention.
Specific embodiment
1HNMR、13CNMR uses Waters with BRUKER ACF-400 type Nuclear Magnetic Resonance, high resolution mass spectrum (HRMS)
The measurement of Synapt G2 type mass spectrograph.Melting point compound (mp) is measured with BUCHIM-565 type melting point apparatus.Below with reference to specific reality
It applies example and further invention is made to the present invention, but limit the scope of the invention.
Embodiment 1
(1) 2- nitro-phenanthridines -6 (5H) -one (B) is synthesized:
HNO is added in 250mL three-necked bottle31.3g and H2SO410mL is placed under the conditions of ice salt bath and stirs, and maintains temperature 0
DEG C, the H dissolved with (5H) -one of phenanthridines -6 1.85g is added dropwise by constant pressure funnel2SO4Then 2mL maintains 0 DEG C of temperature reaction about
2h, TLC detect fully reacting, and reaction solution is poured into 300mL mixture of ice and water, stirring while adding, there is solid analysis after ice-out
Out, it filters, it is 2- nitro-phenanthridines -6 (5H) -one (B), yield 64.8% that filter cake vacuum drying, which obtains yellow solid,.
(2) 2- amino-phenanthridines -6 (5H) -one (C):
Iron powder 1.7g and NH are added in the eggplant-shape bottle of 100mL4Cl 0.8g adds ethyl alcohol (30mL), water (10mL),
2- nitro-phenanthridines -6 (5H) -one (B) 0.9g is added in above-mentioned system, 80 DEG C are reacted 2 hours, are filtered, and distillation under pressure removes molten
Agent, column chromatography for separation obtain 2- amino-phenanthridines -6 (5H) -one (C) (1.04g, 86.7%), white solid.
mp 286.0-287.4℃.1H NMR (400MHz, DMSO-D6) δ 11.33 (s, 1H), 8.30 (d, J=9.1Hz,
1H), 8.22 (d, J=8.1Hz, 1H), 7.82 (t, J=6.9Hz, 1H), 7.59 (t, J=8.0Hz, 1H), 7.48 (d, J=
2.3Hz, 1H), 7.11 (d, J=8.6Hz, 1H), 6.82 (dd, J=8.6,2.3Hz, 1H), 5.01 (s, 2H) .HRMS m/z:
calcd.for C13H11N2O[M+H]+211.0871,found 211.0874
(3) synthesis of N- (6- oxo -5,6- dihydrophenanthridine -2- base) benzsulfamide (1):
By 2- amino-phenanthridines -6 (5H) -one (C) (80mg, 0.5mmol) and benzene sulfonyl chloride, (0.5mmol, formula D structure, R are
Phenyl) (5mL) is dissolved in methylene chloride, then the drop of pyridine 3 is added dropwise, reaction is also added to water after 25 DEG C of room temperature are reacted 2 hours
In, ethyl acetate extraction, column chromatography for separation obtains N- (2- oxo -2H- chromene -6- base) benzsulfamide (1), and yield is
89.3%.
The characterize data of ideal product is as follows: mp 281.5-282.3 DEG C1H NMR(400MHz,DMSO-D6)δ:
11.66 (s, 1H), 10.29 (s, 1H), 8.32 (d, J=7.7Hz, 1H), 8.17 (d, J=8.1Hz, 1H), 7.98 (s, 1H),
7.89 (d, J=4.1Hz, 0H), 7.88 (s, 1H), 7.79 (d, J=7.2Hz, 2H), 7.65 (d, J=7.5Hz, 1H), 7.63-
7.51(m,3H),7.29–7.20(m,2H)；13C NMR(101MHz,DMSO-D6)δ160.8,139.7,134.2,133.9,
133.4,132.5,129.7,128.8,128.1,127.2,126.3,124.1,122.5,118.2,117.4,116.0；HRMS
m/z:calcd.for C19H15N2O3S[M+H]+351.0803,found 351.0808。
Embodiment 2
The synthesis of N- (6- oxo -5,6- dihydrophenanthridine -2- base) hexamethylene sulfonamide (2): specific preparation method is referring to implementation
Example 1, R is cyclohexyl, obtained yield 79.2% in step (3) Chinese style D structure.
The characterize data of ideal product is as follows: mp 230.2-230.9 DEG C1H NMR(500MHz,DMSO-D6)δ
11.75 (s, 1H), 9.82 (s, 1H), 8.35 (d, J=7.7Hz, 1H), 8.27 (d, J=8.1Hz, 1H), 8.16 (s, 1H),
7.91 (t, J=7.3Hz, 1H), 7.68 (t, J=7.4Hz, 1H), 7.42 (d, J=8.7Hz, 1H), 7.37 (d, J=8.7Hz,
1H), 3.02 (t, J=10.1Hz, 1H), 2.08 (d, J=12.0Hz, 2H), 1.76 (s, 2H), 1.64-1.53 (m, 2H), 1.44
(d, J=10.2Hz, 2H), 1.21 (d, J=12.3Hz, 2H)13C NMR(126MHz,DMSO-D6)δ161.0,134.1,
133.8,133.6,133.3,128.7,128.1,126.4,123.3,122.7,118.36,117.5,114.7,59.4,58.8,
27.8,26.5,25.8,25.5,25.2,24.8.HRMS m/z:calcdfor C19H21N2O3S[M+H]+357.1273,found
357.1264。
Embodiment 3
The synthesis of penta sulfonamide (3) of N- (6- oxo -5,6- dihydrophenanthridine -2- base) ring: specific preparation method is referring to implementation
Example 1, R is cyclopenta, obtained yield 65.3% in step (3) Chinese style D structure.
The characterize data of ideal product is as follows: mp 226.3-226.9 DEG C1H NMR(400MHz,DMSO-D6)δ
11.71 (s, 1H), 9.76 (s, 1H), 8.34 (d, J=7.9Hz, 1H), 8.29 (d, J=8.1Hz, 1H), 8.12 (d, J=
1.9Hz, 1H), 7.91 (t, J=7.6Hz, 1H), 7.68 (t, J=7.5Hz, 1H), 7.37 (dd, J=12.9,5.4Hz, 2H),
1.96–1.85(m,4H),1.71–1.61(m,2H),1.58–1.48(m,2H),1.28–1.15(m,3H).13C NMR
(101MHz,DMSO-D6)δ160.9,134.0,133.9,133.5,133.4,128.8,128.1,126.2,124.0,122.7,
118.4,117.5,115.4,60.1,27.9,25.9.HRMS m/z:calcd.forC18H19N2O3S[M+H]+343.1116,
found 343.1112。
Embodiment 4
The synthesis of N- (6- oxo -5,6- dihydrophenanthridine -2- base) third sulfonamide (4): specific preparation method is referring to embodiment
1, R is n-propyl, yield 80.4% in step (3) Chinese style D structure.
The characterize data of ideal product is as follows: mp 214.6-214.9 DEG C1H NMR(500MHz,DMSO-D6)δ
11.74 (s, 1H), 9.88 (s, 1H), 8.35 (d, J=7.4Hz, 1H), 8.29 (d, J=8.0Hz, 1H), 8.18 (s, 1H),
7.89 (s, 1H), 7.68 (t, J=7.4Hz, 1H), 7.42 (d, J=10.4Hz, 2H), 3.14-3.05 (m, 2H), 1.74 (dd, J
=15.0,7.5Hz, 2H), 0.96 (t, J=7.4Hz, 3H)13C NMR(126MHz,DMSO-D6)δ161.0,134.1,
134.0,133.4,133.34,128.7,128.1,126.3,123.8,122.7,118.4,117.5,115.4,52.7,17.2,
13.1.HRMS m/z:calcd.for C16H17N2O3S[M+H]+317.0960,found 317.0956。
Embodiment 5
The synthesis of N- (6- oxo -5,6- dihydrophenanthridine -2- base) fourth sulfonamide (5): specific preparation method is referring to embodiment
1, R is normal-butyl, yield 93.1% in step (3) Chinese style D structure.
The characterize data of ideal product is as follows: mp 213.7-214.6 DEG C1H NMR(500MHz,DMSO-D6)δ
11.74 (s, 1H), 9.83 (s, 1H), 8.35 (d, J=32.3Hz, 2H), 8.17 (s, 1H), 7.93 (s, 1H), 7.71 (s, 1H),
7.41 (s, 2H), 3.13 (d, J=1.1Hz, 2H), 1.73 (d, J=1.2Hz, 2H), 1.39 (d, J=5.7Hz, 2H), 0.86
(s,3H).13C NMR(126MHz,DMSO-D6)δ161.0,134.1,134.1,133.5,133.3,128.8,128.7,
128.2,126.38,123.8,123.8,122.7,118.4,117.6,115.4,115.3,50.7,25.6,21.2,
14.0.HRMSm/z:calcd.for C17H19N2O3S[M+H]+331.1116,found 331.1107。
Embodiment 6
The synthesis of the chloro- N- of 4- (6- oxo -5,6- dihydrophenanthridine -2- base) benzsulfamide (6): specific preparation method is referring to real
Example 1 is applied, R is 4- chlorphenyl, yield 86.2% in step (3) Chinese style D structure.
The characterize data of ideal product is as follows: mp 268.4-268.9 DEG C1H NMR(500MHz,DMSO-D6)δ:
11.71 (s, 1H), 10.39 (s, 1H), 8.34 (d, J=7.9Hz, 1H), 8.21 (d, J=8.2Hz, 1H), 8.03 (s, 0H),
8.01 (d, J=2.1Hz, 1H), 7.93-7.84 (m, 1H), 7.81-7.73 (m, 2H), 7.71-7.65 (m, 1H), 7.66-7.60
(m, 2H), 7.28 (d, J=8.7Hz, 1H), 7.21 (dd, J=8.7,2.2Hz, 1H)13C NMR(126MHz,DMSO-D6)δ:
160.9,138.2–138.1,134.5,133.9,133.5,132.1,129.9,129.2,128.8,128.1,126.3,
124.4,122.5,118.3,117.5,116.4.HRMS m/z:calcd.forC19H14ClN2O3S[M+H]+385.0414,
found 385.0398。
Embodiment 7
The synthesis of 4- methoxyl group-N- (6- oxo -5,6- dihydrophenanthridine -2- base) benzsulfamide (7): specific preparation method ginseng
According to embodiment 1, R is 4- methoxyphenyl, yield 91.0% in step (3) Chinese style D structure.
The characterize data of ideal product is as follows: mp 285.8-286.7 DEG C1H NMR(500MHz,DMSO-D6)δ:
11.64 (s, 1H), 10.14 (s, 1H), 8.30 (d, J=8.7Hz, 1H), 8.15 (d, J=8.1Hz, 1H), 7.97 (d, J=
1.8Hz, 1H), 7.85 (t, J=7.6Hz, 1H), 7.70 (d, J=8.9Hz, 2H), 7.63 (t, J=7.5Hz, 1H), 7.21
(dt, J=8.7,5.4Hz, 2H), 7.02 (d, J=8.9Hz, 2H), 3.74 (s, 3H)13C NMR(126MHz,DMSO-D6)δ:
162.9,160.9,134.0,133.5,132.8,131.4,129.5,128.7,128.1,126.3,123.9,122.5,
118.1,117.4,115.6,114.8,56.0.HRMS m/z:calcd.for C20H17N2O4S[M+H]+381.0909,found
381.0892。
Embodiment 8
The synthesis of 4- tert-butyl-n-(6- oxo -5,6- dihydrophenanthridine -2- base) benzsulfamide (8): specific preparation method ginseng
According to embodiment 1, R is 4- tert-butyl-phenyl, yield 81.8% in step (3) Chinese style D structure.
The characterize data of ideal product is as follows: mp 267.4-267.7 DEG C1H NMR(500MHz,DMSO-D6)δ
11.67(s,1H),10.28(s,1H),8.33(s,1H),8.11(s,1H),7.96(s,1H),7.86(s,1H),7.70(d,J
=42.4Hz, 3H), 7.56 (s, 2H), 7.28 (s, 2H), 1.22 (s, 9H)13C NMR(126MHz,DMSO-D6)δ161.0,
156.4,137.2,134.1,134.0,133.5,132.7,128.8,128.2,128.2,127.2,126.6,126.3,
124.0,124.0,122.4,122.4,118.2,117.3,117.4,115.7,115.6,35.6,31.9.HRMS m/z:
calcd.for C23H23N2O3S[M+H]+407.1429,found 407.1426。
Embodiment 9
The synthesis of 3- cyano-N- (6- oxo -5,6- dihydrophenanthridine -2- base) benzsulfamide (9): specific preparation method reference
Embodiment 1, R is 3- cyano-phenyl, yield 79.2% in step (3) Chinese style D structure.
The characterize data of ideal product is as follows: mp 290.6-291.3 DEG C1H NMR(500MHz,DMSO-D6)δ
11.78 (d, J=34.8Hz, 1H), 10.54 (d, J=34.4Hz, 1H), 8.45 (s, 1H), 8.42-8.30 (m, 2H), 8.27
(t, J=8.6Hz, 1H), 8.20-8.11 (m, 2H), 8.09 (d, J=7.5Hz, 1H), 8.01 (d, J=6.1Hz, 1H), 7.92
(dd, J=19.4,11.5Hz, 1H), 7.86-7.76 (m, 1H), 7.77-7.66 (m, 1H), 7.44-7.22 (m, 2H)13C NMR
(126MHz,DMSO-D6)δ161.0,161.0,141.1,141.0,137.1,137.0,134.7,134.7,133.6,133.5,
131.8,131.7,131.3,131.3,130.8,130.8,128.9,128.8,128.2,128.1,126.4,126.3,
124.7,124.6,122.7,122.6,118.4,118.4,117.9,117.9,117.6,117.6,117.0,116.9,
113.0,113.0.HRMS m/z:calcd.forC20H14N3O3S[M+H]+376.0756,found 376.0756。
Embodiment 10
The synthesis of the chloro- N- of 2- (6- oxo -5,6- dihydrophenanthridine -2- base) benzsulfamide (10): specific preparation method reference
Embodiment 1, R is 2- chlorphenyl, yield 79.8% in step (3) Chinese style D structure.
The characterize data of ideal product is as follows: mp 275.4-275.8 DEG C1H NMR(500MHz,DMSO-D6)δ
11.72 (s, 1H), 10.72 (s, 1H), 8.32 (d, J=7.9Hz, 1H), 8.16 (d, J=8.1Hz, 1H), 8.10 (dd, J=
7.9,1.4Hz, 1H), 8.04 (d, J=1.9Hz, 1H), 7.90 (dd, J=11.2,4.1Hz, 1H), 7.70-7.64 (m, 2H),
7.63-7.58 (m, 1H), 7.51 (dd, J=11.8,4.5Hz, 1H), 7.29 (dd, J=9.4,7.3Hz, 2H)13C NMR
(126MHz,DMSO-D6)δ160.8,136.9,135.1,134.0,133.8,133.51,132.3,132.1,131.9,
131.3,128.8,128.2,126.31,123.3,122.4,118.2,117.5,114.9.HRMS m/z:calcd.for
C19H14ClN2O3S[M+H]+385.0414,found 385.0406。
Embodiment 11
The synthesis of 2- methoxyl group-N- (6- oxo -5,6- dihydrophenanthridine -2- base) benzsulfamide (11): specific preparation method
Referring to embodiment 1, R is 2- methoxyphenyl, yield 81.3% in step (3) Chinese style D structure.
The characterize data of ideal product is as follows: mp 298.4-299.3 DEG C1H NMR(400MHz,DMSO-D6)δ:
11.61 (s, 1H), 9.98 (s, 1H), 8.34-8.27 (m, 1H), 8.15 (d, J=8.1Hz, 1H), 7.98 (d, J=1.5Hz,
1H), 7.92-7.85 (m, 1H), 7.77 (dd, J=7.8,1.6Hz, 1H), 7.65 (t, J=7.5Hz, 1H), 7.56-7.50 (m,
1H), 7.22 (dd, J=9.8,5.3Hz, 2H), 7.17 (d, J=8.3Hz, 1H), 7.00 (t, J=7.6Hz, 1H), 3.95 (s,
3H)；13CNMR(101MHz,DMSO-D6)δ:160.9,156.8,135.6,133.9,133.5,132.8,130.8,128.7,
128.2,126.6,126.3,123.5,122.3,120.6,118.0,117.2,115.0,113.2,56.6.HRMS m/z:
calcd.for C20H17N2O4S[M+H]+381.0909,found381.0905。
Embodiment 12
The synthesis of the chloro- N- of 2- methoxyl group -5- (6- oxo -5,6- dihydrophenanthridine -2- base) benzsulfamide (12): specific preparation
Method is referring to embodiment 1, and R is the chloro- 2- methoxyphenyl of 5-, yield 72.6% in step (3) Chinese style D structure.
The characterize data of ideal product is as follows: mp 298.4-298.8 DEG C1H NMR(400MHz,DMSO-D6)δ:
11.65 (s, 1H), 10.17 (s, 0H), 10.17 (s, 1H), 8.32 (d, J=7.9Hz, 1H), 8.18 (d, J=8.2Hz, 1H),
7.99 (s, 1H), 7.87 (s, 1H), 7.71 (s, 1H), 7.70 (s, 0H), 7.66 (t, J=7.5Hz, 1H), 7.61 (dd, J=
8.9,2.6Hz, 1H), 7.23 (d, J=9.6Hz, 3H), 3.96 (s, 3H)；13C NMR(101MHz,DMSO-D6)δ:160.9,
155.8,135.1,134.2,133.9,133.6,132.2,129.8,128.8,128.2,126.3,124.2 123.8,
122.3,118.1,117.4,115.5,57.1.HRMS m/z:calcd.for C20H16N2O4S[M+H]+415.0519,found
415.0522。
The nuclear magnetic spectrum of compound 12 is as shown in Figure 1 in the present invention；The carbon spectrum of compound 12 is as shown in Figure 2 in the present invention；
The high resolution mass spectrum of compound 12 is as shown in Figure 3 in the present invention.
Embodiment 13
The synthesis of N- (6- oxo -5,6- dihydrophenanthridine -2- base) thiophene -2- sulfonamide (13): specific preparation method reference
Embodiment 1, R is 2- thienyl, yield 75.5% in step (3) Chinese style D structure.
The characterize data of ideal product is as follows: mp 296.8-297.1 DEG C1H NMR(500MHz,DMSO-D6)δ:
11.81-11.69 (m, 1H), 10.51 (dd, J=21.1,9.9Hz, 1H), 8.34 (d, J=7.4Hz, 1H), 8.20 (d, J=
7.7Hz, 1H), 8.13-8.01 (m, 1H), 7.90 (d, J=6.8Hz, 2H), 7.76-7.65 (m, 1H), 7.60 (d, J=
17.4Hz, 1H), 7.31 (dt, J=21.7,10.7Hz, 2H), 7.21-7.07 (m, 1H)13C NMR(126MHz,DMSO-D6)
δ:161.0,140.2,134.5,134.3,133.6,133.5,133.0,132.3,128.1,126.3,124.4,122.5,
117.4,116.3.HRMS m/z:calcd.for C17H13N2O3S2[M+H]+357.0368,found 357.0366。
Embodiment 14
The synthesis of N- (6- oxo -5,6- dihydrophenanthridine -2- base) naphthalene -2- sulfonamide (14): specific preparation method is referring to real
Example 1 is applied, R is 2- naphthalene, yield 85.9% in step (3) Chinese style D structure.
The characterize data of ideal product is as follows: mp 291.4-292.3 DEG C1H NMR(500MHz,DMSO-D6)δ
11.68 (s, 1H), 10.55 (s, 1H), 8.51 (s, 1H), 8.31 (d, J=7.3Hz, 1H), 8.19 (d, J=7.6Hz, 1H),
8.12 (t, J=8.5Hz, 2H), 8.08 (s, 1H), 8.00 (d, J=7.5Hz, 1H), 7.87 (t, J=8.4Hz, 2H), 7.66
(d, J=7.8Hz, 2H), 7.64-7.60 (m, 1H), 7.26 (d, J=6.5Hz, 2H)13C NMR(126MHz,DMSO-D6)δ
160.9,136.9,134.7,134.2,133.9,133.4,132.5,132.0,129.9,129.7,129.5,128.7,
128.6,128.3,128.1,126.3,124.0,122.7,122.5,118.2,117.4,115.9.HRMSm/z:calcd.for
C23H17N2O3S[M+H]+401.0960,found 401.0968。
Embodiment 15
The synthesis of N- (6- oxo -5,6- dihydrophenanthridine -2- base) -2,3- Dihydrobenzofuranes -5- sulfonamide (15): specific
Preparation method is referring to embodiment 1, and R is 2,3- Dihydrobenzofuranes -5- base, yield 91.9% in step (3) Chinese style D structure.
The characterize data of ideal product is as follows: mp 280.4-280.9 DEG C1H NMR(500MHz,DMSO-D6)δ
11.65 (s, 1H), 10.15 (s, 1H), 8.31 (d, J=7.1Hz, 1H), 8.17 (d, J=6.8Hz, 1H), 7.99 (s, 1H),
7.87 (s, 1H), 7.65 (s, 2H), 7.55 (d, J=7.9Hz, 1H), 7.35-7.17 (m, 2H), 6.84 (d, J=6.7Hz,
1H), 4.67-4.46 (m, 2H), 3.18 (d, J=7.2Hz, 2H)13C NMR(126MHz,DMSO-D6)δ163.7,160.9,
134.0,133.5,132.9,131.5,129.2,128.7,128.2,126.3,124.6,123.8,122.4,118.2,
117.3,115.5,109.8,72.6,28.2.HRMS m/z:calcd.for C21H17N2O4S[M+H]+393.0909,found
393.0899。
Application examples
(1) BRD4 protein binding capacity is tested
AlphaScreen method:
1) material: BRD4 albumen；HTRF KinEASE (Cisbio, France)；MgCl2,MnCl2,DTT；384 low volumes
Blank (Corning, USA)；Pipette tips (Axygen, USA)；DMSO (Sigma, USA)
2) method: the albumen reaction buffer and peptide substrates of 5 μ L is added in every hole, and 10 μ L of compound is incubated for 30 minutes, mixing
Object is further incubated at room temperature 2 hours, and the stop bath that 5 μ L are added terminates reaction, is detected using EnVision multiple labeling reader
Fluorescence signal ratio, obtained data are analyzed using Graphpad Prism 5.
Reality of compound (1)~(15) that testing example obtains according to the method described above to the 503nhibiting concentration of BRD4 albumen
It is as shown in table 2 below to test result.
Table 2
| Number | Activity (BRD4) IC50(μM) | Number | Activity (BRD4) IC50(μM) |
| 1 | 1.64 | 9 | 1.79 |
| 2 | 5.92 | 10 | 1.25 |
| 3 | 6.17 | 11 | 0.48 |
| 4 | 6.71 | 12 | 0.24 |
| 5 | 5.54 | 13 | 6.74 |
| 6 | 0.79 | 14 | 7.23 |
| 7 | 1.32 | 15 | 13.12 |
| 8 | 1.13 |
(2) anti-tumor activity is tested
Mtt assay: being made into individual cells suspension with culture solution is obtained containing 10% tire calf serum, thin with every hole 1000-10000
Born of the same parents are inoculated into 96 orifice plates, and every pore volume 200uL adds the drug of respective concentration, cultivate 3-5 days, every hole adds MTT solution (5mg/ml
Prepared with PBS, pH=7.4) 20uL.Continue to be incubated for 4h, terminates culture, careful inhale abandons culture supernatant in hole, thin for suspending
Born of the same parents, which need to inhale again after being centrifuged, abandons culture supernatant in hole.Every hole adds 150uL DMSO, vibrates 10min, melts crystal sufficiently.
490nm wavelength is selected, measures each hole absorbance value on enzyme linked immunological monitor, record is as a result, using the time as abscissa, extinction
Value is that ordinate draws cell growth curve.
And compound (13) is calculated to the 503nhibiting concentration (IC of different tumor cell lines according to cell inhibitory rate50Value),
Concrete outcome is as shown in table 3 below.
Table 3
| Tumor type | Cell strain | IC50(μM) |
| Lung cancer | A549 | 0.75 |
| Liver cancer | HepG2 | 4.83 |
| Cancer of pancreas | PANC-1 | 6.70 |
| Gastric cancer | SGC-7901 | 5.35 |
The above results show that phenanthridines ketone compounds provided by the present invention have good BRD4 inhibitory effect, and to more
Kind tumour has good inhibiting effect.
Claims (10)
1. a kind of phenanthridines ketone compounds with BRD4 albumen inhibiting effect, which is characterized in that be formula (I) compound represented
And its pharmaceutically acceptable salt；
In formula (I), R is selected from C1~C6Alkyl, C3~C6Naphthenic base, thienyl, 2,3- dihydro benzo furyl, it is unsubstituted or by
The phenyl and naphthalene that substituent group replaces；The substituent group is halogen, cyano, hydroxyl, amino, sulfydryl, C1~C6Alkyl, C1~C6
Alkoxy, C1~C6Alkylamino or C1~C6Halogenated alkoxy.
2. the phenanthridines ketone compounds according to claim 1 with BRD4 albumen inhibiting effect, which is characterized in that change
Close object 1~15；
In compound 1, R is
In compound 2, R is
In compound 3, R is
In compound 4, R is
In compound 5, R is
In compound 6, R is
In compound 7, R is
In compound 8, R is
In compound 9, R is
In compound 10, R is
In compound 11, R is
In compound 12, R is
In compound 13, R is
In compound 14, R is
In compound 15, R is
3. the phenanthridines ketone compounds according to claim 1 with BRD4 albumen inhibiting effect, which is characterized in that described
Pharmaceutically acceptable salt, comprising: formula (I) compound represented and acid formed acid salt and logical formula (I) shown in change
Close the basic salt that object and inorganic base are formed.
4. the preparation of described in any item phenanthridines ketone compounds with BRD4 albumen inhibiting effect according to claim 1~3
Method, which comprises the following steps:
1) using formula A structure compound represented as raw material, in HNO3/H2SO4Nitration mixture under the conditions of carry out nitration reaction, obtain formula B
Nitro compound shown in structure；
2) nitro compound shown in formula B structure, obtains intermediate shown in formula C-structure after nitro-reduction reaction；
3) intermediate shown in formula C-structure obtains formula with sulfonyl chloride compound shown in formula D structure after sulfonamide reaction
(I) the phenanthridines ketone compounds of structure shown in.
Wherein, the R in formula D and the R in formula (I) have identical meanings.
5. the preparation method according to claim 4, which is characterized in that in step 1), the condition of the nitration reaction are as follows:
In -5~5 DEG C of 1~5h of progress.
6. the preparation method according to claim 4, which is characterized in that in step 2), the item of the nitro-reduction reaction
Part are as follows: iron powder and NH is added4Cl and second alcohol and water react 1~3 hour at 70 DEG C~90 DEG C.
7. the preparation method according to claim 4, which is characterized in that in step 3), the item of the sulfonamide reaction
Part are as follows: in dichloromethane solvent, using pyridine as catalyst, 15 DEG C~35 DEG C are reacted 1~5 hour.
8. a kind of pharmaceutical composition, which is characterized in that including the described in any item phenanthridines ketone compounds of claims 1 to 3 and
Pharmaceutically acceptable auxiliary material.
9. described in any item phenanthridines ketone compounds are preparing the application in BRD4 protein inhibitor according to claim 1~3.
10. described in any item phenanthridines ketone compounds have in preparation prevention or/and treatment with BRD4 according to claim 1~3
Application in the drug of related disorders, which is characterized in that the disease be melanoma, Papillary thyroid carcinoma, cholangiocarcinoma,
Colon cancer, oophoroma, center line cancer, non-small cell lung cancer, malignant lymphatic tumor, liver cancer, kidney, lung cancer, cancer of pancreas, bladder cancer,
Prostate cancer, breast cancer, cancer of pancreas, thyroid cancer, cutaneum carcinoma, colorectal cancer, cancer of pancreas, oophoroma, breast cancer, testis
Cancer, osteocarcinoma, the cancer of the brain, the cancer of the esophagus, gastrointestinal cancer, soft-tissue tumor, leukemia or lymph cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910601362.9A CN110256346A (en) | 2019-07-03 | 2019-07-03 | Phenanthridines ketone compounds and preparation method and application with BRD4 albumen inhibiting effect |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910601362.9A CN110256346A (en) | 2019-07-03 | 2019-07-03 | Phenanthridines ketone compounds and preparation method and application with BRD4 albumen inhibiting effect |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110256346A true CN110256346A (en) | 2019-09-20 |
Family
ID=67924511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910601362.9A Pending CN110256346A (en) | 2019-07-03 | 2019-07-03 | Phenanthridines ketone compounds and preparation method and application with BRD4 albumen inhibiting effect |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110256346A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6277990B1 (en) * | 1999-12-07 | 2001-08-21 | Inotek Corporation | Substituted phenanthridinones and methods of use thereof |
| US20020006927A1 (en) * | 2000-05-19 | 2002-01-17 | Jia-He Li | Sulfonamide and carbamide derivatives of 6(5H)phenanthridinones and their uses |
-
2019
- 2019-07-03 CN CN201910601362.9A patent/CN110256346A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6277990B1 (en) * | 1999-12-07 | 2001-08-21 | Inotek Corporation | Substituted phenanthridinones and methods of use thereof |
| US20020006927A1 (en) * | 2000-05-19 | 2002-01-17 | Jia-He Li | Sulfonamide and carbamide derivatives of 6(5H)phenanthridinones and their uses |
Non-Patent Citations (2)
| Title |
|---|
| YANLE ZHI ET AL.,: "Novel phenanthridin-6(5H)-one derivatives as potent and selective BET bromodomain inhibitors:Rational design,synthesis and biological evaluation", 《EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY》 * |
| 郑春满 等编著: "《高等合成化学方法与实践》", 30 September 2018, 北京：国防工业出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102075886B1 (en) | Novel pyrazolo [3,4-d] pyrimidine compounds or salts thereof | |
| Liu et al. | Design, synthesis and biological evaluation of novel thieno [3, 2-d] pyrimidine derivatives possessing diaryl semicarbazone scaffolds as potent antitumor agents | |
| Hou et al. | Design, synthesis and biological evaluation of novel 7-amino-[1, 2, 4] triazolo [4, 3-f] pteridinone, and 7-aminotetrazolo [1, 5-f] pteridinone derivative as potent antitumor agents | |
| Wang et al. | Synthesis and anticancer activity evaluation of a series of [1, 2, 4] triazolo [1, 5-a] pyridinylpyridines in vitro and in vivo | |
| CN106749261A (en) | One class substituted triazole and piperazines PARP inhibitor and its production and use | |
| Moarbess et al. | New IKK inhibitors: Synthesis of new imidazo [1, 2-a] quinoxaline derivatives using microwave assistance and biological evaluation as IKK inhibitors | |
| CN110563703A (en) | compound for inducing PARP-1 degradation based on CRBN ligand, preparation method and application | |
| CN105541825A (en) | Preparation method of triazole derivatives and application of triazole derivatives as drugs | |
| Belal | Synthesis, molecular docking and antitumor activity of novel pyrrolizines with potential as EGFR-TK inhibitors | |
| CN107129506B (en) | As pyrimido [4,5-d] [1,3] oxazines -2- ketone derivatives of EGFR inhibitor and its application | |
| CN109824640A (en) | A kind of coumarin kind compound and its pharmaceutical composition, preparation method and application | |
| CN101475513A (en) | Raf and HDAC small molecular double inhibitor, and preparation and use thereof | |
| CN113366008B (en) | CD73 inhibitor, preparation method and application thereof | |
| Li et al. | Synthesis and Bioevaluation of Thieno [2, 3‐d] pyrimidinone Derivatives as Potential Tumor Cell Growth Inhibitors | |
| CN105646371B (en) | The 2,4- diaryl-amine yl pyrimidines analog derivative of the segment containing hydroxamic acid and preparation and application | |
| CN116496219A (en) | Six-membered and five-membered heterocyclic compound, and pharmaceutical composition and application thereof | |
| CN108358894B (en) | Compound for inhibiting histone acetyltransferase as well as preparation method and application thereof | |
| Liu et al. | Design, synthesis, and bioactivity study on Lissodendrins B derivatives as PARP1 inhibitor | |
| CN110256346A (en) | Phenanthridines ketone compounds and preparation method and application with BRD4 albumen inhibiting effect | |
| CN116444517A (en) | Carboxamide compound and application thereof in preparation of deubiquitinase USP28 inhibitor | |
| CN115477639A (en) | Multi-substituted pyrimidine compound with FGFR1 as target spot, and preparation method and application thereof | |
| CN117043153A (en) | Heterocyclic compounds as GLS1 inhibitors | |
| Gao et al. | Rational synthesis and evaluation of 2, 4-diamino-thieno [2, 3-d] pyrimidines as antitumor agents | |
| KR102325163B1 (en) | Process for preparing a compound | |
| TW201738227A (en) | Fused ring compound and preparation method, application and intermediate compound thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190920 |